A majority of ovarian cancer patients presenting with diseases at late stages have poor survival rates. Efforts to improve this with more effective screening methods are clearly desirable. Traditionally, screening for ovarian cancer has focused on imaging or the use of serum markers. However, the high cost of imaging and the failure of 20 years of research to discover any better biomarkers than CA125, suggests a new approach would be worthwhile. Therefore, besides using serum samples for biomarker discovery, we will explore the option of using urine as an alternative body fluid to discover the potential peptide markers, which may ultimately be transformed into a reliable home screening test. This pilot project will test the hypothesis that urinary peptides, which normally are small size, thermodynamically stable and less interactive, could be useful urinary markers for ovarian cancer. In this project, we propose to: 1.) Apply innovative proteomic technologies such as multidimensional liquid chromatography (MD-LC), mass spectrometry, fluorescent labeling with two-dimensional differential gel electrophoresis (2D-DIGE) to generate urinary peptide profiles from the classified ovarian cancer subtypes and the age-matched healthy women. 2.) Using bio-informatic tools to select, identify and characterize the novel urinary peptides including modifications, which are specifically associated with ovarian cancers. 3.) Develop the reliable urine immunoassays and normalization methods, and apply the panel of urinary markers for validation in a large study including pre-operative urine specimens and normal controls. This project, if successful, could fundamentally shift the approach to the early detection of ovarian cancer and significantly improve the survival rate of cases detected. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA111949-01A1
Application #
6966599
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Patriotis, Christos F
Project Start
2005-09-01
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$199,291
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Zhang, Lifang; Wang, Dan; Jiang, Wei et al. (2010) Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 8:74
Aponte, Margarita; Jiang, Wei; Lakkis, Montaha et al. (2008) Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68:5839-48
Gagnon, Audrey; Ye, Bin (2008) Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 20:9-13
Shin, Injae; Zamfir, Alina D; Ye, Bin (2008) Protein carbonhydrate Analysis: gel-based staining, liquid chromatography, mass spectrometry, and microarray screening. Methods Mol Biol 441:19-39
Ye, Bin; Gagnon, Audrey; Mok, Samuel C (2007) Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4:121-31
Ye, Bin; Aponte, Margarita; Dai, Yan et al. (2007) Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett 251:43-52
Ye, Bin; Skates, Steven; Mok, Samuel C et al. (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432-41